Abstract
Disseminated forms of neuroblastoma (NB), a tumor derived from neuroectodermal tissue, pose a major therapeutic challenge for pediatric oncology. By performing a comparative cDNA array analysis of metastatic neuroblasts versus primary xenograft from the human IGR-N-91 NB model, we were able to identify a set of downregulated developmental genes in metastatic neuroblasts. One of these genes was Wnt-5a, a member of the Wnt signaling pathway, known to be involved in the development of neural crest cells. Since we also found a significant decrease in Wnt-5a mRNA in unfavorable versus favorable categories in 37 primary NB tumors (P<0.007), we wondered whether retinoic acid (RA), which has a role in neural crest induction and differentiation, might reverse the aberrant negative regulation of Wnt-5a in metastatic malignant neuroblasts. Following treatment with 10 μ M RA for 6 days, the MYCN-amplified IGR-N-91 cell lines underwent neuronal differentiation as assessed by reduced MYCN gene expression and neuritic extension. In these conditions, data showed an upregulation of Wnt-5a and PKC-θ isoform expressions. Our study highlights, for the first time, the involvement of Wnt-5a, which has a role in embryonic and morphogenetic processes, in the response of malignant neuroblasts to RA. In conclusion, we demonstrated that RA, which is used in the treatment of high-risk NB patients with recurrent/residual disease in the bone marrow, is able to upregulate Wnt-5a gene expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aigner L, Arber S, Kapfhammer JP, Laux T, Schneider C, Botteri F, Brenner HR and Caroni P . (1995). Cell, 83, 269–278.
Blanc E, Goldschneider D, Ferrandis E, Barrois M, Le Roux G, Leonce S, Douc-Rasy S, Bénard J and Raguénez G . (2003). Am. J. Pathol., 163, 321–331.
Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM and Drabkin HA . (2000). Proc. Natl. Acad. Sci. USA, 97, 12776–12781.
Cha KB, Douglas KR, Potok MA, Liang H, Jones SN and Camper SA . (2004). Mech. Dev., 121, 183–194.
Christiansen JH, Coles EG and Wilkinson DG . (2000). Curr. Opin. Cell Biol., 12, 719–724.
Datta R, Kojima H, Yoshida K and Kufe D . (1997). J. Biol. Chem., 272, 20317–20320.
Douc-Rasy S, Barrois M, Echeynne M, Kaghad, Blanc E, Raguénez G, Goldschneider D, Terrier-Lacombe MJ, Hartmann O, Moll U, Caput D and Bénard J . (2002). Am. J. Pathol., 160, 631–639.
Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD and Sklar J . (1991). Cell, 66, 649–661.
Ferrandis E, da Silva J, Riou G and Bénard J . (1994). Cancer Res., 54, 2256–2261.
Garcia-Castro MI, Marcelle C and Bronner-Fraser M . (2002). Science, 297, 848–851.
Huguet EL, Smith K, Bicknell R and Harris AL . (1995). J. Biol. Chem., 270, 12851–12856.
Ikeya M, Lee SM, Johnson JE, McMahon AP and Takada S . (1997). Nature, 389, 966–970.
Iozzo RV, Eichstetter I and Danielson KG . (1995). Cancer Res., 55, 3495–3499.
Jönsson M and Andersson TJ . (2001). J. Cell Sci., 11, 2043–2053.
Jönsson M, Dejmek J, Bendahl P and Andersson T . (2002). Cancer Res., 62, 409–416.
Katoh M, Hirai M, Sugimura T and Terada M . (1996). Oncogene, 13, 873–876.
Katoh M . (2002). Int. J. Mol. Med., 10, 683–687.
Körner M, Tarentino N, Pleskoff O, Lee LM and Debré P . (1995). J. Neurochem., 62, 1716–1726.
Kühl M, Sheldahl LC, Park M, Miller JR and Moon RT . (2000). Trends Genet., 16, 279–283.
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB and Reynolds CP . (1999). N. Engl. J. Med., 341, 1165–1173.
Miller JR, Hocking AM, Brown JD and Moon RT . (1999). Oncogene, 18, 7860–7872.
Monks CRF, Kupfer H, Tamir I, Barlow A and Kupfer A . (1997). Nature, 385, 83–86.
Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, Wilder E, Rustgi A, Kitajewski J, Gabrielson E, Bremmes R, Franklin W and Drabkin HA . (2003). Proc. Natl. Acad. Sci. USA, 100, 10429–10434.
Olson DJ, Gibo DM, Saggers G, Debinski W and Kumar R . (1997). Cell Growth Differ., 8, 417–423.
Pahlman S, Hoehner JC, Naberg E, Hedborg F, Fagerstrom S, Gestblom C, Johansson I, Larsson U, Lavenius E, Örtoft E and Söderholm H . (1995). Eur. J. Cancer, 31A, 453–458.
Passalacqua M, Patrone M, Sparatore B, Melloni E and Montremoli S . (1999). Biochem. J., 337, 113–118.
Polakis P . (2000). Genes Dev., 14, 1837–1851.
Raguénez G, Lantrua V, Désiré L and Courtois Y . (1999). Biochem. Biophys. Res. Commun., 258, 745–751.
Reynolds CP, Matthay KK, Villablanca JG and Maurer BJ . (2003). Cancer Lett., 197, 185–192.
Slepko N, Patrizio M and Levi C . (1999). J. Neurosci. Res., 57, 33–38.
Sparatore B, Patrone M, Passalacqua M, Pedrazzi M, Pontremoli S and Melloni E . (2000a). Biochem. Biophys. Res. Commun., 275, 149–153.
Sparatore B, Patrone M, Passalacqua M, Pedrazzi M, Pontremoli S and Melloni E . (2000b). Biochem. Biophys. Res. Commun., 275, 589–594.
Taipale J and Beachy PA . (2001). Nature, 411, 349–354.
Tang S, Morgan KG, Parker C and Ware JA . (1997). J. Biol. Chem., 272, 28704–28711.
Thiele CJ, Reynolds CP and Israel MA . (1985). Nature, 313, 404–406.
Wakeman JA, Walsh J and Andrews PW . (1998). Oncogene, 17, 179–186.
Wechsler-Reya RJ and Scott MP . (1999). Neuron, 22, 103–114.
Weeraratna A, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M and Trent JM . (2002). Cancer Cell, 1, 279–288.
Yamaguchi TP, Bradley A, McMahon AP and Jones S . (1999). Development, 126, 1211–1223.
Zeidman R, Pettersson L, Sailaja PR, Truedsson E, Fagerström S, Pahlman S and Larsson C . (1999). Int. J. Cancer, 81, 494–501.
Acknowledgements
We thank SFCE, Dr O Hartmann, Dr Dominique Valteau-Couanet (Service de Pédiatrie), Dr Serge Koscielny (Département de Santé Publique), and Dr Marie-José Terrier-Lacombe (Service d'anatomo-pathologie). We are also grateful to Michel Barrois for his invaluable assistance in designing the gene probes, Sabrina Cantais and Nadine Béron-Gaillard for their technical assistance (all from Institut Gustave Roussy). We also thank Dr Ashani T Weeraratna and Dr Yuan Jiang from the National Human Genome Research Institute/USA for donating the PcDNA3-Wnt-5a. Edited by Englishbooster S.A. This work was supported by the Ligue contre le Cancer, Comité de Montbéliard.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blanc, E., Roux, G., Bénard, J. et al. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene 24, 1277–1283 (2005). https://doi.org/10.1038/sj.onc.1208255
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208255
Keywords
This article is cited by
-
miR-139-3p/Wnt5A Axis Inhibits Metastasis in Hepatoblastoma
Molecular Biotechnology (2023)
-
ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation
Journal of Biomedical Science (2021)
-
The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment
Cancer and Metastasis Reviews (2020)
-
WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages
British Journal of Cancer (2018)
-
Sea turtle fibropapilloma tumors share genomic drivers and therapeutic vulnerabilities with human cancers
Communications Biology (2018)